Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proteon Therapeutics Slumps On Phase III Study Miss In CKD

Executive Summary

Shares in Proteon Therapeutics lost nearly three-quarters of their value on news that its first Phase III trial for its lead product vonapanitase had failed. Undeterred, however, the company is increasing the size of its second pivotal study on the back of positive data from certain key endpoints.

Advertisement

Related Content

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded
Proteon plans Ph III for elastase in kidney disease surgery

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel